[ Price : $8.95]
FDA places a partial clinical hold on Curis TakeAim Lymphoma study a of emavusertib in patients with B-cell malignancies.[ Price : $8.95]
A new Politico investigation details FDAs mishandling of food safety oversight, which may draw renewed interest from Capitol Hill ...[ Price : $8.95]
FDA reminds healthcare providers that radiological computer-aided triage and notification devices for intracranial large vessel oc...[ Price : $8.95]
Vanda Pharmaceuticals files a lawsuit to compel FDA to produce drug review records associated with the companys supplemental NDA f...[ Price : $8.95]
FDA lifts a Gilead Sciences partial clinical hold on studies evaluating its investigational agent magrolimab in combination with a...[ Price : $8.95]
FDA Review posts the latest Federal Register notices for the week ending 4/8/2022.[ Price : $8.95]
Federal Register notice: FDA makes available two medical device guidance documents for the Safety and Performance Based Pathway.[ Price : $8.95]
Federal Register notice: FDA makes available a final guidance entitled E8(R1) General Considerations for Clinical Studies.